Across TCGA pan-cancer cohorts, BCAM Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCAM data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher BCAM Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated BCAM expression acts as an unfavorable survival marker, although some lineages such as STAD and HNSC show a favorable association.

OV, LUSC, and STAD are the cancer types where BCAM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →
LUSC	OS	Median	III,IV	0.112	0.664	.020	14	view →
STAD	DFS	Median	III,IV	1.000	0.331	.028	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	DFS	Median	All	1.000	0.307	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BCAM tumor-vs-normal RNA expression · all BCAM data types